Literature DB >> 29789315

Quinoline-3-carboxamides such as tasquinimod are not specific inhibitors of S100A9.

Martin Pelletier1, Jean-Christophe Simard2, Denis Girard2, Philippe A Tessier1.   

Abstract

Entities:  

Year:  2018        PMID： 29789315      PMCID： PMC5965053          DOI： 10.1182/bloodadvances.2018016667

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  5 in total

1.  Neutrophils and the S100A9 protein critically regulate granuloma formation.

Authors:  Yuya Yoshioka; Tatsuaki Mizutani; Satoshi Mizuta; Ayumi Miyamoto; Satoru Murata; Toshiaki Ano; Hiroshi Ichise; Daisuke Morita; Hiroyuki Yamada; Yoshihiko Hoshino; Tatsuaki Tsuruyama; Masahiko Sugita
Journal:  Blood Adv       Date:  2016-12-14

2.  Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.

Authors:  John T Isaacs; Roberto Pili; David Z Qian; Susan L Dalrymple; Jason B Garrison; Natasha Kyprianou; Anders Björk; Anders Olsson; Tomas Leanderson
Journal:  Prostate       Date:  2006-12-01       Impact factor: 4.104

3.  Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.

Authors:  Anders Olsson; Anders Björk; Johan Vallon-Christersson; John T Isaacs; Tomas Leanderson
Journal:  Mol Cancer       Date:  2010-05-17       Impact factor: 27.401

Review 4.  Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer.

Authors:  Neha Gupta; Omar Al Ustwani; Li Shen; Roberto Pili
Journal:  Onco Targets Ther       Date:  2014-02-12       Impact factor: 4.147

5.  Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.

Authors:  Per Björk; Anders Björk; Thomas Vogl; Martin Stenström; David Liberg; Anders Olsson; Johannes Roth; Fredrik Ivars; Tomas Leanderson
Journal:  PLoS Biol       Date:  2009-04-28       Impact factor: 8.029
  5 in total
  1 in total

Review 1.  DAMPening Mortality in COVID-19: Therapeutic Insights From Basic Cardiometabolic Studies on S100A8/A9.

Authors:  Nordin M J Hanssen; Bart Spaetgens; Prabhakara R Nagareddy; Andrew J Murphy
Journal:  Circulation       Date:  2021-01-12       Impact factor: 29.690
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.